343 related articles for article (PubMed ID: 29708042)
21. Bufo alvarius: a potent hallucinogen of animal origin.
Weil AT; Davis W
J Ethnopharmacol; 1994 Jan; 41(1-2):1-8. PubMed ID: 8170151
[TBL] [Abstract][Full Text] [Related]
22. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
Davis AK; Xin Y; Sepeda N; Averill LA
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):587-596. PubMed ID: 37734158
[No Abstract] [Full Text] [Related]
23. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.
Shen HW; Jiang XL; Yu AM
Drug Metab Dispos; 2011 Jul; 39(7):1227-34. PubMed ID: 21464174
[TBL] [Abstract][Full Text] [Related]
24. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Halberstadt AL; Nichols DE; Geyer MA
Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
[TBL] [Abstract][Full Text] [Related]
25. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Riga MS; Soria G; Tudela R; Artigas F; Celada P
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
[TBL] [Abstract][Full Text] [Related]
26. Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors.
Alhaider AA; Hamon M; Wilcox GL
Eur J Pharmacol; 1993 Nov; 249(2):151-60. PubMed ID: 7507056
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
28. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects.
Uthaug MV; Davis AK; Haas TF; Davis D; Dolan SB; Lancelotta R; Timmermann C; Ramaekers JG
J Psychopharmacol; 2022 Mar; 36(3):309-320. PubMed ID: 33949246
[TBL] [Abstract][Full Text] [Related]
29. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.
Uthaug MV; Lancelotta R; Szabo A; Davis AK; Riba J; Ramaekers JG
Psychopharmacology (Berl); 2020 Mar; 237(3):773-785. PubMed ID: 31822925
[TBL] [Abstract][Full Text] [Related]
30. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
Soussan C; Kjellgren A
Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
[TBL] [Abstract][Full Text] [Related]
31. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
32. The use of classic psychedelics among adults: a Danish online survey study.
Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
[TBL] [Abstract][Full Text] [Related]
33. Plants and mushrooms of abuse.
Spoerke DG; Hall AH
Emerg Med Clin North Am; 1990 Aug; 8(3):579-93. PubMed ID: 2201522
[TBL] [Abstract][Full Text] [Related]
34. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
35. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
Krebs-Thomson K; Ruiz EM; Masten V; Buell M; Geyer MA
Psychopharmacology (Berl); 2006 Dec; 189(3):319-29. PubMed ID: 17013638
[TBL] [Abstract][Full Text] [Related]
36. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
37. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
39. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Ott J
J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
[TBL] [Abstract][Full Text] [Related]
40. Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R; Kumar Bora P; Saikia J; Konwar P; Sarkar A; Kemprai P; Proteem Saikia S; Haldar S; Slater A; Banik D
Phytochemistry; 2024 Feb; 218():113928. PubMed ID: 38035973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
